Armodafinil, a wakefulness‑promoting drug used to treat sleep disorders such as narcolepsy, obstructive sleep apnea, and shift work sleep disorder, was developed in the early 2000s and approved for medical use in the late 2000s. Its history is marked by its effectiveness in promoting alertness and improving daytime functioning, along with ongoing evaluation of its safety profile and potential for misuse. Armodafinil, the R‑enantiomer of modafinil, was approved in the United States in 2007 and is widely prescribed as a once‑daily treatment. Its development included clinical trials demonstrating prolonged wakefulness effects compared to modafinil, as well as post‑marketing surveillance programs to monitor long‑term safety and efficacy.
BRAND NAMES
Nuvigil – the most widely known and original brand
Waklert – commonly available in India
Artvigil – another popular generic version
MECHANISM OF ACTION
Armodafinil promotes wakefulness primarily by acting on the central nervous system, although its exact mechanism is not completely understood. It functions mainly by inhibiting the reuptake of dopamine through binding to the dopamine transporter (DAT), which increases dopamine levels in brain regions responsible for alertness and cognition. In addition to its dopaminergic effects, it indirectly modulates other neurotransmitters such as norepinephrine, histamine, glutamate, and GABA, contributing to enhanced cortical activity and sustained wakefulness.
PHARMACOKINETICS :
Absorption : Armodafinil is well absorbed after oral administration, with peak plasma concentrations typically reached within about 2 hours. Food may delay its absorption slightly but does not significantly affect overall bioavailability.
Distribution : Armodafinil is moderately distributed throughout the body and is approximately 60% bound to plasma proteins, mainly albumin. It is able to cross the blood–brain barrier, allowing it to exert its effects on the central nervous system.
Metabolism : Armodafinil is primarily metabolized in the liver through hydrolytic and oxidative pathways, involving cytochrome P450 enzymes (mainly CYP3A4). Its metabolites are largely inactive.
Elimination :
Armodafinil is eliminated mainly through the kidneys in the form of inactive metabolites. It has a relatively long elimination half‑life of about 12–15 hours, allowing for once‑daily dosing.
PHARMACODYNAMICS
Armodafinil enhances wakefulness and alertness by increasing dopaminergic activity in the brain through inhibition of dopamine reuptake. It also modulates other neurotransmitters such as norepinephrine, histamine, and glutamate while reducing GABAergic activity, leading to improved cognitive function and sustained vigilance.
ADMINISTRATION
Armodafinil is administered orally, usually once daily. It is typically taken in the morning for conditions like narcolepsy or obstructive sleep apnea, and about one hour before the start of a work shift in shift work sleep disorder.
DOSAGE AND STRENGTH
Armodafinil is typically prescribed in doses of 150–250 mg once daily, depending on the condition being treated. It is commonly available in tablet strengths of 50 mg, 150 mg, and 250 mg.
DRUG INTERACTIONS
Armodafinil may induce CYP3A4, reducing the effectiveness of drugs such as oral contraceptives, and inhibit CYP2C19, which can increase levels of certain drugs like Diazepam and Omeprazole. Caution is also needed when used with other central nervous system stimulants, as this may enhance side effects like anxiety, insomnia, or increased heart rate.
FOOD INTERACTIONS
However, a high‑fat meal may slightly delay its absorption, leading to a slower onset of action, though the overall effectiveness is not significantly affected.
CONTRAINDICATIONS
Armodafinil is contraindicated in patients with a known hypersensitivity to armodafinil or to Modafinil. It should be used with caution in individuals with a history of severe skin reactions or hypersensitivity syndromes. Additionally, caution is advised in patients with significant cardiovascular conditions or severe hepatic impairment.
SIDE EFFECTS
Armodafinil may cause several side effects, which are usually mild to moderate. Common effects include headache, nausea, dizziness, insomnia, dry mouth, and anxiety. Some individuals may also experience decreased appetite or increased heart rate. Rare but serious adverse effects include severe skin reactions (such as Stevens–Johnson syndrome), hypersensitivity reactions, psychiatric symptoms (e.g., agitation or hallucinations), and cardiovascular complications. Immediate medical attention is required if severe reactions occur.
OVER DOSE
Severe headache
Anxiety or agitation
Trouble sleeping (insomnia)
Fast or irregular heartbeat
High blood pressure
Nausea or vomiting
Confusion
TOXICITY
Armodafinil generally has low acute toxicity when used at prescribed doses, but overdose can lead to symptoms such as agitation, insomnia, anxiety, nausea, tachycardia, and elevated blood pressure. Severe toxicity may result in central nervous system overstimulation, confusion, or cardiac complications. Management is mainly supportive, including monitoring of vital signs and symptomatic treatment, as there is no specific antidote.
